Common lymphatic endothelial and vascular endothelial receptor-1 mediates the transmigration of regulatory T Cells across human hepatic sinusoidal endothelium

Research output: Contribution to journalArticle

Abstract

Background/Aims Non-cirrhotic intrahepatic portal hypertension (NCIPH) is generally regarded to have a benign prognosis. We have studied a cohort followed-up at a tertiary referral center and postulate that gut-derived prothrombotic factors may contribute to the pathogenesis and prognosis of NCIPH. Methods We retrospectively analyzed prognostic indicators in 34 NCIPH patients. We also searched for associated gut diseases. Results Transplant-free survival in NCIPH patients from first presentation with NCIPH at 1, 5, and 10 years was 94% (SE: 4.2%), 84% (6.6%), and 69% (9.8%), respectively. Decompensated liver disease occurred in 53% of patients. Three (9%) patients had ulcerative colitis while five of 31 (16%) tested had celiac disease and on Kaplan-Meier analysis, celiac disease predicted reduced transplantfree survival (p = 0.018). On multivariable Cox regression analysis, independent predictors of reduced transplant-free survival were older age at first presentation with NCIPH, hepatic encephalopathy, and portal vein thrombosis. Prevalence of elevated initial serum IgA anticardiolipin antibody (CLPA) was significantly higher in NCIPH (36% of patients tested), compared to Budd-Chiari syndrome (6%) (p = 0.032, Fisher's exact test) and celiac disease without concomitant liver disease (0%) (p = 0.007). Conclusions We have identified prognostic factors and report progression to liver failure in 53% of NCIPH patients followed-up at our center. Our data supports a role for intestinal disease in the pathogenesis of intrahepatic portal vein occlusion leading to NCIPH.

Details

Original languageEnglish
Pages (from-to)4147-4155
Number of pages9
JournalJournal of Immunology
Volume186
Issue number7
Publication statusPublished - 1 Apr 2011

Keywords

  • Inflammatory bowel disease, Portal vein thrombosis, IgA cardiolipin antibody, Celiac disease, Non-cirrhotic portal hypertension